Table 2

Patient Clinical and Quality-of-Life Measurements (Total N = 120)

Measure

mean (SD)

Total Sample

(n = 120)

GOLD

Stage 1

(n = 23)

GOLD

Stage 2

(n = 53)

GOLD

Stage 3

(n = 27)

GOLD

Stage 4

(n = 17)

ANOVA

ANOVA

KWT


F-stat

RE

p-value

p-value


FEV1 (%)

58.4 (24.8)

92.9 (13.7)

65.5 (9.1)

37.4 (5.7)

23.0 (4.8)

254.2

<0.001

<0.001

6MWT (m)

312.5 (108.0)

356.7 (124.3)

321.0 (95.8)

315.0 (98.8)

222.5 (89.6)

6.01

<0.001

<0.001

Borg Dyspnea

2.48 (1.64)

1.19 (1.11)

2.33 (1.65)

3.48 (1.67)

3.12 (0.49)

11.55

<0.001

<0.001

SGRQ Total

41.3 (19.7)

28.8 (15.0)

37.2 (18.6)

52.2 (19.6)

54.1 (13.5)

11.15

Ref

<0.001

<0.001

SGRQ Symptom

50.0 (24.1)

42.4 (21.4)

46.8 (23.9)

60.1 (26.1)

54.4 (20.2)

2.98

0.27

0.03

0.02

SGRQ Activity

57.3 (27.6)

38.0 (23.8)

53.5 (28.1)

65.7 (23.0)

82.5 (10.0)

12.36

1.11

<0.001

<0.001

SGRQ Impact

29.9 (18.9)

19.4 (14.9)

25.8 (16.3)

41.9 (20.0)

37.8 (17.5)

9.34

0.84

<0.001

<0.001

SF-36 PCS

34.4 (9.6)

39.5 (10.1)

34.4 (10.7)

32.4 (7.8)

30.9 (4.2)

3.49

0.31

0.02

0.002

SF-36 MCS

49.6 (10.9)

52.60 (9.4)

50.5 (10.4)

47.9 (12.5)

45.5 (10.7)

1.75

0.16

0.16

0.114

EQ-5D US Index

0.73 (0.19)

0.80 (0.13)

0.70 (0.21)

0.72 (0.19)

0.72 (0.16)

1.35

0.11

0.26

0.079

EQ-5D UK Index

0.63 (0.27)

0.73 (0.19)

0.59 (0.32)

0.63 (0.25)

0.63 (0.24)

1.38

0.12

0.25

0.069

EQ-5D VAS

65.3 (18.9)

74.3 (16.3)

66.2 (20.0)

60.1 (18.4)

58.7 (15.8)

3.31

0.30

0.02

0.004


GOLD: global burden of obstructive lung disease; Ref: Reference; RE: Relative efficiency ratio; SGRQ: St. George's Respiratory Questionnaire; ref: reference; ANOVA: analysis of variance; KWT: Kruskal-Wallis test

Pickard et al. Health and Quality of Life Outcomes 2011 9:26   doi:10.1186/1477-7525-9-26

Open Data